ADA Scientific Sessions 2025 Abstract·13 JunA Multicenter, Randomized, Open-Label, Controlled Study on Evaluating the Efficacy and Safety of Switching from Daily DPP-4 Inhibitors to Cofrogliptin in Patients with Type 2 Diabetes Mellitus in ChinaTrial in peopleInterventionsPaper